Mesothelioma - The `Orphan` Cancer

Released on: October 10, 2007, 12:30 am

Press Release Author: The Law Offices of James Sokolove

Industry: Law

Press Release Summary: Government funding remains elusive for deadly disease

Press Release Body: While Americans have long been romanced by campaigns for breast
cancer and leukemia research, it may be some time before mesothelioma enjoys a stint
in the spotlight. Despite the fact that over 2,500 cases of the disease are
diagnosed in the U.S. each year-with as many or more dying from it-the need to
develop effective treatments for mesothelioma victims continues to be overlooked by
the federal government.

"Even though it has been medically documented since the 1940s, mesothelioma remains
very much an 'orphan' disease today," says Attorney Jim Sokolove, principal and
founder of the Law Offices of James Sokolove (www.jimsokolove.com). "The government
has yet to recognize this disease as the epidemic that it really is."

Between 2000 and 2003, the National Cancer Institute (NCI) invested less than $2
million annually in clinical research for mesothelioma-a fraction of the funds
invested in other types of cancers. And although Congress has allocated $3.75
billion for research on various diseases since 1992, none of this money has been
allocated to furthering mesothelioma studies. With no effective treatments
available, the disease is almost always fatal, with an average survival time of 12
months following diagnosis.

Sokolove cites complex economic and political factors among the many reasons why
mesothelioma has failed to receive significant national funding. \"Although enormous
financial resources are available to help improve mesothelioma treatment, there is
no real effort to commit these resources."

One group is lobbying aggressively to reverse the rising tide of mesothelioma deaths
in the U.S. The Mesothelioma Applied Research Foundation (MARF) coordinates numerous
efforts to advance funding, studies and treatment for the disease. In 2005, MARF
succeeded in obtaining from Congress the first appropriation ever for mesothelioma
research.

The Law Offices of James Sokolove worked closely with MARF in the development of its
new website, the Mesothelioma Resource Center (www.mesorc.com), a comprehensive
support and information resource for mesothelioma victims and their families.

"MARF is doing extraordinary things in getting the voice of the mesothelioma
community to be heard," Sokolove remarks. "Through the Mesothelioma Resource Center,
the LOJS hopes to compliment their efforts and provide much-needed support to
victims and their loved ones."

Those interested in learning more about mesothelioma research, clinical trials, and
treatments can register for free updates at www.mesorc.com. For each person that
signs up, the Law Offices of James Sokolove will make a $200 donation to MARF.

About The Law Offices of James Sokolove
The Law Offices of James Sokolove (LOJS) is the nation's largest and fastest growing
marketer of legal services, providing qualified law firms, with the most cost
efficient and highly qualified case leads. For over 30 years, the LOJS has
endeavored to reinvent how people obtain legal services, in order to provide
everyone, irrespective of ethnicity or income, equal access to our civil justice
system and within it, superior quality of representation and service. Working with
an affiliate network of over 300 law firm throughout the US, the LOJS generates over
200,000 leads and 12,000 signed cases annually, translating into over one quarter
billion in revenue dollars for its affiliates. As the legal profession continues to
experience unprecedented and dynamic change, the LOJS business model is a proven
success as it strategically matches specific client needs with particular law firm
expertise.


Web Site: http://

Contact Details: The Law Offices of James Sokolove,
1340 Centre St # 102,
Newton Center,
Massachusetts MA 02459

Martin Lock
Phone: 617-742-0696 Ext 413
Fax: 617-964-4336
Email: mlock@jimsokolove.com
URL: www.jimsokolove.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •